OBJECTIVE: The objective was to describe and compare types and duration of symptoms among women with invasive versus borderline ovarian tumors. METHODS: Cases were women, ages 20-69 years, diagnosed with invasive (616) and borderline (151) epithelial ovarian tumors from 1994 to 1998. Symptoms were obtained using a standardized in-person interview. Differences in types and duration of symptoms, time to diagnosis after consulting a physician, and primary reason for diagnosis by invasive/borderline status and histologic type were determined using bivariate and regression analyses controlling for age. RESULTS: Borderline and invasive cases reported similar types of symptoms. However, borderline cases were twice as likely to report not having had symptoms as invasive cases (16 vs 8%, P = 0.005). Prediagnostic symptom duration was longer among borderline versus invasive cases (median: 6 vs 4 months, P < 0.001). The median time from first consultation with a physician to diagnosis (1 month) did not differ by invasive/borderline status. Borderline cases were twice as likely to be diagnosed through routine examination as invasive cases (28 vs 16%, P = 0.001). Invasive cases were more likely to be diagnosed because of symptoms (62 vs 48%, P = 0.002). CONCLUSIONS: Because most (90%) women with ovarian tumors have symptoms and median symptom duration is 4 months, greater awareness of symptoms by women and physicians is needed for the earlier detection of ovarian tumors. The lesser likelihood of being detected by routine examination and the shorter symptom duration for invasive versus borderline cases underscores the need for effective screening and preventive strategies. (c)2001 Elsevier Science.
OBJECTIVE: The objective was to describe and compare types and duration of symptoms among women with invasive versus borderline ovarian tumors. METHODS: Cases were women, ages 20-69 years, diagnosed with invasive (616) and borderline (151) epithelial ovarian tumors from 1994 to 1998. Symptoms were obtained using a standardized in-person interview. Differences in types and duration of symptoms, time to diagnosis after consulting a physician, and primary reason for diagnosis by invasive/borderline status and histologic type were determined using bivariate and regression analyses controlling for age. RESULTS: Borderline and invasive cases reported similar types of symptoms. However, borderline cases were twice as likely to report not having had symptoms as invasive cases (16 vs 8%, P = 0.005). Prediagnostic symptom duration was longer among borderline versus invasive cases (median: 6 vs 4 months, P < 0.001). The median time from first consultation with a physician to diagnosis (1 month) did not differ by invasive/borderline status. Borderline cases were twice as likely to be diagnosed through routine examination as invasive cases (28 vs 16%, P = 0.001). Invasive cases were more likely to be diagnosed because of symptoms (62 vs 48%, P = 0.002). CONCLUSIONS: Because most (90%) women with ovarian tumors have symptoms and median symptom duration is 4 months, greater awareness of symptoms by women and physicians is needed for the earlier detection of ovarian tumors. The lesser likelihood of being detected by routine examination and the shorter symptom duration for invasive versus borderline cases underscores the need for effective screening and preventive strategies. (c)2001 Elsevier Science.
Authors: Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Rayna K Matsuno; Michael E Carney; Marc T Goodman Journal: Gynecol Oncol Date: 2010-06-29 Impact factor: 5.482
Authors: Bo Qin; Patricia G Moorman; Linda E Kelemen; Anthony J Alberg; Jill S Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Edward S Peters; Ann G Schwartz; Paul Terry; Joellen M Schildkraut; Elisa V Bandera Journal: Am J Epidemiol Date: 2017-06-15 Impact factor: 4.897
Authors: Mary Anne Rossing; Kristine G Wicklund; Kara L Cushing-Haugen; Noel S Weiss Journal: J Natl Cancer Inst Date: 2010-01-28 Impact factor: 13.506
Authors: Sean M Devlin; Paula H Diehr; M Robyn Andersen; Barbara A Goff; Patrick T Tyree; William E Lafferty Journal: J Womens Health (Larchmt) Date: 2010-03 Impact factor: 2.681
Authors: Kimberly A Lowe; M Robyn Andersen; Nicole Urban; Pamela Paley; Charles W Dresher; Barbara A Goff Journal: Gynecol Oncol Date: 2009-05-07 Impact factor: 5.482
Authors: Chioma O Erondu; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Edward Peters; Ann G Schwartz; Paul D Terry; Kristin Wallace; Lucy Akushevich; Frances Wang; Sydnee Crankshaw; Andrew Berchuck; Joellen M Schildkraut; Patricia G Moorman Journal: J Womens Health (Larchmt) Date: 2016-02-17 Impact factor: 2.681
Authors: Bo Qin; Patricia G Moorman; Anthony J Alberg; Jill S Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Edward S Peters; Ann G Schwartz; Paul Terry; Joellen M Schildkraut; Elisa V Bandera Journal: Br J Nutr Date: 2015-12-16 Impact factor: 3.718
Authors: Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Marc T Goodman Journal: Gynecol Oncol Date: 2009-05-22 Impact factor: 5.482